ARGNF News and Press, Argen X NV From 03/06/23

2023-03-06 17:07:59 ET Summary Immunovant's lead drug, batoclimab, is one of many FcRn antagonists, either approved or in development, for the treatment of autoimmune diseases, including myasthenia gravis (MG). In batoclimab clinical trials by Immunovant, safety concerns emerged w...

argenx SE (ARGX) Q4 2022 Earnings Conference Call March 2, 2023 08:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Tazeen Ahmad...

The following slide deck was published by argenx SE in conjunction with their 2022 Q4 earnings call. For further details see: argenx SE 2022 Q4 - Results - Earnings Call Presentation

$ 1 7 3 million in fourth quarter and $ 401 million in full year 2022 VYVGART® (efgartigimod alfa- fcab ) global net product sales FDA review ongoing for SC efgartigimod BLA with PDUFA target action date of June 20, 2023...

Karen Massey appointed as Chief Operating Officer, effective March 13, 2023 Keith Woods to retire and serve as Advisor on argenx Board of Directors March 2 , 202 3 Amsterdam , the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunol...

February 27, 2023 Amsterdam , the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders h...

February 2 7 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participa...

Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund gained 14.85% (Institutional Shares) during the final quarter of 2022. We enter...

Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended December 31, 2022, Baron Health Care Fund rose 9.08% (Institutional Shares) vs. the 11.54% gai...

Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. The Fund was down 7.1% (Institutional Shares) during the fourth quarter, compared to a gain of 2.2% for the Russell...